Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: A review of currently used methods

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 3, 2013, Pages 239-250

  Marcellin, Fabienne ^a   Spire, Bruno ^b   Carrieri, Maria Patrizia ^b   Roux, Perrine ^b  

^a AIX MARSEILLE UNIV   (France)

^b NONE

Author keywords

adherence; antiretroviral therapy; ART; clinical trial; HAART; HIV

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4 LYMPHOCYTE COUNT; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SELF REPORT; TREATMENT DURATION; VIRUS LOAD; VISUAL ANALOG SCALE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84874591273     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.13.8     Document Type: Review

References (98)

1. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133(1), 21-30 (2000).
2. Bangsberg DR, Perry S, Charlebois ED et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15(9), 1181-1183 (2001).
3. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J. Antimicrob. Chemother. 53(5), 696-699 (2004).
4. Oyugi JH, Byakika-Tusiime J, Ragland K et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fxed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21(8), 965-971 (2007).
5. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J. Clin. Epidemiol. 50(4), 385-391 (1997).
6. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J. Acquir. Immune Defc. Syndr. 43(Suppl. 1), S149-S155 (2006).
7. Miller LG, Hays RD. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin. Trials 1(1), 36-46 (2000).
8. Fisher JD, Amico KR, Fisher WA et al.; LifeWindows Team. Computer-based intervention in HIV clinical care setting improves antiretroviral adherence: the LifeWindows Project. AIDS Behav. 15(8), 1635-1646 (2011).
9. Mullen BA, Cook K, Moore RD et al Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs. BMC Infect. Dis. 11, 45 (2011).
10. Kalichman SC, Cherry C, Kalichman MO et al. Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. Am. J. Public Health 101(3), 531-538 (2011).
11. Ingersoll KS, Farrell-Carnahan L, Cohen-Filipic J et al. A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+ crack cocaine users. Drug Alcohol Depend. 116(1-3), 177-187 (2011).
12. Holstad MM, Diiorio C, Kelley ME, Resnicow K, Sharma S. Group motivational interviewing to promote adherence to antiretroviral medications and risk reduction behaviors in HIV infected women. AIDS Behav. 15(5), 885-896 (2011).
13. Holstad MM, Diiorio C, McCarty F. Adherence, sexual risk, and viral load in HIV-infected women prescribed antiretro-viral therapy. AIDS Patient Care STDS 25(7), 431-438 (2011).
14. Wilson IB, Laws MB, Safren SA et al. Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIV. J. Acquir. Immune Defc. Syndr. 53(3), 338-347 (2010).
15. Knaf GJ, Bova CA, Fennie KP, O'Malley JP, Dieckhaus KD, Williams AB. An analysis of electronically monitored adherence to antiretroviral medications. AIDS Behav. 14 (4), 755-768 (2010).
16. Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 21(8), 976-983 (2009).
17. Simoni JM, Huh D, Frick PA et al. Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J. Acquir. Immune Defc. Syndr. 52(4), 465-473 (2009).
18. Contardo C, Black AC, Beauvais J, Dieckhaus K, Rosen MI. Relationship of prospective memory to neuropsychological function and antiretroviral adherence. Arch. Clin. Neuropsychol. 24(6), 547-554 (2009).
19. Berg KM, Mouriz J, Li X, Duggan E, Goldberg U, Arnsten JH. Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics. Contemp. Clin. Trials 30(5), 481-489 (2009).
20. Reynolds NR, Testa MA, Su M et al.; AIDS Clinical Trials Group 731 and 384 Teams. Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. J. Acquir. Immune Defc. Syndr. 47(1), 62-68 (2008).
21. Sorensen JL, Haug NA, Delucchi KL et al. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 88(1), 54-63 (2007).
22. Simoni JM, Pantalone DW, Plummer MD, Huang B. A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women. Health Psychol. 26(4), 488-495 (2007).
23. Rathbun RC, Farmer KC, Lockhart SM, Stephens Jr. Validity of a stage of change instrument in assessing medication adherence in indigent patients with HIV infection. Ann. Pharmacother. 41(2), 208-214 (2007).
24. Gardner EM, Hullsiek KH, Telzak EE et al.; Terry Beirn Community Programs for Clinical Research on AIDS and the International Network for Strategic Initiatives in Global HIV Trials. Antiretro-viral medication adherence and class-spe-cifc resistance in a large prospective clinical trial. AIDS 24(3), 395-403 (2010).
25. Campo RE, Cohen C, Grimm K, Shangguan T, Maa J, Seekins D. Switch from protease inhibitor-to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients. Int. J. STD AIDS 21(3), 166-171 (2010).
26. Gardner EM, Sharma S, Peng G et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 22(1), 75-82 (2008).
27. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lami-vudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin. Trials 9(3), 164-176 (2008).
28. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J. Acquir. Immune Defc. Syndr. 46(5), 547-554 (2007).
29. Kozal MJ, Hullsiek KH, Macarthur RD et al.; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clin. Trials 8(6), 357-370 (2007).
30. Gulick RM, Lalama CM, Ribaudo HJ et al. Intensifcation of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS 21(7), 813-823 (2007).
31. Mannheimer S, Thackeray L, Huppler Hullsiek K et al.; Terry Beirn Community Program for Clinical Research on AIDS. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care 20(2), 161-169 (2008).
32. Mepham S, Zondi Z, Mbuyazi A, Mkhwanazi N, Newell ML. Challenges in PMTCT antiretroviral adherence in northern KwaZulu-Natal, South Africa. AIDS Care 23 (6), 741-747 (2011).
33. Mbuagbaw L, Thabane L, Ongolo-Zogo P, Lang T. The challenges and opportunities of conducting a clinical trial in a low resource setting: the case of the Cameroon mobile phone SMS (CAMPS) trial, an investigator initiated trial. Trials 12, 145 (2011).
34. Lester RT, Ritvo P, Mills EJ et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 376(9755), 1838-1845 (2010).
35. Lester RT, Mills EJ, Kariri A et al. The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials 10, 87 (2009).
36. Chang LW, Kagaayi J, Nakigozi G et al. Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. PLoS One 5 (6), e10923 (2010).
37. Pearson CR, Micek MA, Simoni JM et al. Randomized control trial of peer-delivered, modifed directly observed therapy for HAART in Mozambique. J. Acquir. Immune Defc. Syndr. 46(2), 238-244 (2007).
38. Mosam A, Shaik F, Uldrick TS et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J. Acquir. Immune Defc. Syndr. 60 (2), 150-157 (2012).
39. Laurent C, Kouanfack C, Laborde-Balen G et al.; Stratall ANRS 12110/ESTHER study group. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect. Dis. 11(11), 825-833 (2011).
40. Firnhaber C, Azzoni L, Foulkes AS et al. Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS ONE 6(6), e21450 (2011).
41. Wester CW, Thomas AM, Bussmann H et al. Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. AIDS 24(Suppl. 1), S27-S36 (2010).
42. Danel C, Moh R, Chaix ML et al.; Trivacan ANRS 1269 Trial Group. Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults. J. Infect. Dis. 199(1), 66-76 (2009).
43. Kiwuwa-Muyingo S, Walker AS, Oja H et al.; DART Trial Team. The impact of frst year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. Trop. Med. Int. Health 17(5), 584-594 (2012).
44. Muyingo SK, Walker AS, Reid A et al.; DART Trial Team. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the frst year of the DART trial in Uganda and Zimbabwe. J. Acquir. Immune Defc. Syndr. 48(4), 468-475 (2008).
45. Uzma Q, Emmanuel F, Ather U, Zaman S. Effcacy of interventions for improving antiretroviral therapy adherence in HIV/AIDS cases at PIMS, Islamabad. J. Int. Assoc. Physicians AIDS Care (Chic). 10(6), 373-383 (2011).
46. Wang H, Zhou J, Huang L, Li X, Fennie K P, Williams AB. Effects of nurse-delivered home visits combined with telephone calls on medication adherence and quality of life in HIV-infected heroin users in Hunan of China. J. Clin. Nurs. 19(3-4), 380-388 (2010).
47. Parienti JJ, Massari V, Reliquet V et al.; POSOVIR Study Group. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study. AIDS 21(16), 2217-2222 (2007).
48. Lambert-Niclot S, Flandre P, Valantin MA et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J. Infect. Dis. 204(8), 1211-1216 (2011).
49. Cooper V, Moyle GJ, Fisher M et al.; SWEET (Simplifcation With Easier Emtricitabine Tenofovir) group, UK. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz. AIDS Care 23(6), 705-713 (2011).
50. Josephson F, Andersson MC, Flamholc L et al. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naive HIV-1 infected patients. Eur. J. Clin. Pharmacol. 66(4), 349-357 (2010).
51. Berger S, Schad T, von Wyl V et al. Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. AIDS 22(6), 767-775 (2008).
52. Gross R, Tierney C, Andrade A et al.; AIDS Clinical Trials Group A5073 Study Team. Modifed directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Arch. Intern. Med. 169(13), 1224-1232 (2009).
53. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. 'White coat compliance' limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin. Trials 9(4), 238-246 (2008).
54. Cohen CJ, Molina JM, Cahn P et al.; ECHO Study Group; THRIVE Study Group. Effcacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the Phase 3 doubleblind randomized ECHO and THRIVE trials. J. Acquir. Immune Defc. Syndr. 60(1), 33-42 (2012).
55. Molina JM, Lamarca A, Andrade-Villanueva J et al.; Study 145 Team. Effcacy and safety of once daily elvitegra-vir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, Phase 3, non-inferiority study. Lancet Infect. Dis. 12(1), 27-35 (2012).
56. González-García J, Cohen D, Johnson M et al.; M05-730 Study Group. Short communication: Comparable safety and effcacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in anti-retroviral-naive, HIV type 1-infected subjects: 96 week fnal results of the randomized trial M05-730. AIDS Res. Hum. Retroviruses 26(8), 841-845 (2010).
57. Flexner C, Tierney C, Gross R et al.; ACTG A5073 Study Team. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin. Infect. Dis. 50(7), 1041-1052 (2010).
58. Bangsberg DR, Hecht FM, Charlebois ED et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14(4), 357-366 (2000).
59. Bartlett JG. International HIV workshop on management of treatment-experienced patients. Hopkins HIV Rep. 14(6), 4-5 (2002).
60. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J. Antimicrob. Chemother. 61(4), 769-773 (2008).
61. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J. Infect. Dis. 197(Suppl. 3), S272-S278 (2008).
62. Bangsberg DR, Acosta EP, Gupta R et al Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological ftness. AIDS 20(2), 223-231 (2006).
63. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin. Infect. Dis. 43(7), 939-941 (2006).
64. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu. Rev. Public Health 21, 121-145 (2000).
65. Gandhi M, Ameli N, Bacchetti P et al Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS 19(16), 1885-1896 (2005).
66. Carrieri P, Cailleton V, Le Moing V et al.; APROCO study group. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J. Acquir. Immune Defc. Syndr. 28(3), 232-239 (2001).
67. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav. 10(3), 227-245 (2006).
68. Chesney MA, Ickovics JR, Chambers DB et al. Self-reported adherence to anti retroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 12(3), 255-266 (2000).
69. Knobel H, Alonso J, Casado JL et al.; GEEMA Study Group. Validation of a simplifed medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 16(4), 605-613 (2002).
70. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virologi-cal treatment outcome. AIDS 16(2), 269-277 (2002).
71. Holstad MM, Foster V, Diiorio C, McCarty F, Teplinskiy I. An examination of the psychometric properties of the Antiretroviral General Adherence Scale (AGAS) in two samples of HIV-infected individuals. J. Assoc. Nurses AIDS Care 21(2), 162-172 (2010).
72. Marcellin F, Carrieri MP, Peretti-Watel P et al.; VESPA Study Group. Do migrants overreport adherence to highly active antiretroviral therapy?: results from the French VESPA (ANRS-EN12) National Survey. J. Acquir. Immune Defc. Syndr. 42(5), 646-647 (2006).
73. Duran S, Solas C, Spire B et al.; Cohort Manif 2000 Study Group. 'Do HIV-infect-ed injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS 15(8), 1075-1077 (2001).
74. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J. Acquir. Immune Defc. Syndr. 38(4), 445-448 (2005).
75. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immuno-defciency virus-infected persons in clinical trials. Clin. Infect. Dis. 34 (8), 1115-1121 (2002).
76. Liu H, Golin CE, Miller LG et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann. Intern. Med. 134(10), 968-977 (2001).
77. Arnsten JH, Demas PA, Farzadegan H et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin. Infect. Dis. 33 (8), 1417-1423 (2001).
78. Obermeyer MC, Bott S, Carrieri P et al. HIV Testing, Treatment and Prevention: Generic Tools for Operational Research. WHO, Geneva, Switzerland (2009).
79. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J. Acquir. Immune Defc. Syndr. 43(Suppl. 1), S79-S87 (2006).
80. Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, Bangsberg DR. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin. Infect. Dis. 45(7), 908-915 (2007).
81. Kalichman SC, Amaral CM, Cherry C et al. Monitoring medication adherence by unannounced pill counts conducted by telephone: reliability and criterion-related validity. HIV Clin. Trials 9(5), 298-308 (2008).
82. Gross R, Yip B, Lo Re V 3rd et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J. Infect. Dis. 194 (8), 1108-1114 (2006).
83. Messou E, Chaix ML, Gabillard D et al. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J. Acquir. Immune Defc. Syndr. 56(4), 356-364 (2011).
84. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin. Trials 5(2), 74-79 (2004).
85. Back D, Gatti G, Fletcher C et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 16(Suppl. 1), S5-S37 (2002).
86. Parienti JJ, Verdon R, Bazin C, Bouvet E, Massari V, Larouzé B. The pills identifca-tion test: a tool to assess adherence to antiretroviral therapy. JAMA 285(4), 412 (2001).
87. Kouanfack C, Laurent C, Peytavin G et al.; French National Agency for Research on AIDS 1274 Study Group. Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in Cameroon. J. Acquir. Immune Defc. Syndr. 48(2), 216-219 (2008).
88. Kerr T, Walsh J, Lloyd-Smith E, Wood E. Measuring adherence to highly active antiretroviral therapy: implications for research and practice. Curr. HIV/AIDS Rep. 2(4), 200-205 (2005).
89. Parienti JJ, Das-Douglas M, Massari V et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS ONE 3(7), e2783 (2008).
90. Boyer S, Clerc I, Bonono CR, Marcellin F, Bilé PC, Ventelou B. Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: individual and healthcare supply-related factors. Soc. Sci. Med. 72(8), 1383-1392 (2011).
91. WHO. Adherence to Long-Term Therapies: Evidence for Action. WHO, Geneva, Switzerland (2003).
92. Spire B, Duran S, Souville M, Leport C, Raff F, Moatti JP; APROCO cohort study group. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc. Sci. Med. 54(10), 1481-1496 (2002).
93. Carrieri MP, Raff F, Lewden C et al.; APROCO study group. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virologi-cal response: a 3-year follow-up study. Antivir. Ther. (Lond.) 8(6), 585-594 (2003).
94. Haberer JE, Robbins GK, Ybarra M et al. Real-time electronic adherence monitoring is feasible, comparable to unannounced pill counts, and acceptable. AIDS Behav. 16(2), 375-382 (2012).
95. WHO. UNAIDS: Resource Needs for an Expanded Response to AIDS in Low and Middle-Income Countries. WHO, Geneva, Switzerland (2005).
96. Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA. Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis. J. Acquir. Immune Defc. Syndr. 46(4), 402-409 (2007).
97. Ruud KW, Srinivas SC, Toverud EL. Healthcare providers' experiences with adverse drug reactions and adherence challenges in antiretroviral therapy of HIV patients in the Eastern Cape Province, South Africa. Eur. J. Clin. Pharmacol. 68(9), 1321-1328 (2012).
98. Ruud K W, Toverud EL, Radloff S, Srinivas SC. Antiretroviral treatment and follow-up of HIV-infected patients by health care providers in South African public primary health care. J. Assoc. Nurses AIDS Care 21(5), 417-428 (2010).